CFDE Data Portal | Search GAS1RR

	Label	Description
	GAS1RR Gene (Entity type)	ENSG00000226237 - GAS1 adjacent regulatory RNA
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 3 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE181517 doxorubicin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE218060 decitabine T cell 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE178975 GSE178978 EGFR inhibition 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212312 FBXW7 knockout Reh 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

GAS1RR

ENSG00000226237 - GAS1 adjacent regulatory RNA

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 6 human dn

A Gene Set from LINCS

GSE261563 CX-5461 3 v 8 human up

A Gene Set from LINCS

GSE77108 saha 6 v 9 human up

A Gene Set from LINCS

GSE181517 doxorubicin 0 v 1 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 4 human up

A Gene Set from LINCS

GSE218060 decitabine T cell 2 v 4 human up

A Gene Set from LINCS

GSE178975 GSE178978 EGFR inhibition 1 v 0 human up

A Gene Set from LINCS

GSE212312 FBXW7 knockout Reh 2 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.